News & Blog

Moving The Field Toward More Patient-Focused Drug Development

Together with our partners in the Jumpstarting Brain Tumor Drug Development Coalition – Accelerate Brain Cancer Cure (ABC2), Musella Foundation for Brain Tumor Research and Education, and the Society for Neuro-Oncology – NBTS has been advocating for the brain tumor research field to take patients’ quality of life into great account during clinical trials. As […]

So You Heard About Rintega? Here’s What’s Next for Brain Tumor Drug Development

Last week, news broke that a promising clinical trial of a new type of treatment for a subset of glioblastoma (GBM) patients – an immunotherapeutic vaccine made by Celldex Therapeutics called RINTEGA (rindopepimut) – was discontinued because patients receiving the investigational therapy were not doing better than patients in the control arm. As we said in our statement regarding […]

From the CEO’s Desk: Busy Season for Public Policy Kicks Into Gear

The first quarter of the year for the National Brain Tumor Society (NBTS) – and any other organization engaged in proactive advocacy – is a particularly busy time in the area of public policy and government relations. While research initiatives often spillover year-to-year and remain ongoing (like our flagship research initiative, the Defeat GBM Research Collaborative, which is a […]

Share